Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084981 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00084981: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00084981 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084981, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of decitabine and valproic acid in treating patients with non-small cell lung cancer. Drugs used in chemotherapy, such as decitabine and valproic acid, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG decitabine
- DRUG valproic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084981
The ClinicalTrials.gov registry entry for NCT00084981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00084981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084981 about?
NCT00084981 is a clinical study titled "Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer". This phase I trial is studying the side effects and best dose of decitabine and valproic acid in treating patients with non-small cell lung cancer. Drugs used in chemotherapy, such as decitabine and valproic acid, work in different ways to stop tumor cells from dividing so they stop growing or die. ...
What is the current status of trial NCT00084981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-04.
What interventions are being tested in trial NCT00084981?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), decitabine (DRUG), valproic acid (DRUG).
Who is sponsoring clinical trial NCT00084981?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.